These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 4039188)

  • 1. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
    McKenna WJ; Oakley CM; Krikler DM; Goodwin JF
    Br Heart J; 1985 Apr; 53(4):412-6. PubMed ID: 4039188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
    Crick JC
    Br Heart J; 1985 Nov; 54(5):550-1. PubMed ID: 4052297
    [No Abstract]   [Full Text] [Related]  

  • 3. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population.
    Cecchi F; Olivotto I; Montereggi A; Squillatini G; Dolara A; Maron BJ
    Heart; 1998 Apr; 79(4):331-6. PubMed ID: 9616338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
    McKenna WJ; Kleinebenne A
    Herz; 1985 Apr; 10(2):91-101. PubMed ID: 2580767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy.
    McKenna WJ; Harris L; Rowland E; Kleinebenne A; Krikler DM; Oakley CM; Goodwin JF
    Am J Cardiol; 1984 Oct; 54(7):802-10. PubMed ID: 6541429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study.
    Maron BJ; Savage DD; Wolfson JK; Epstein SE
    Am J Cardiol; 1981 Aug; 48(2):252-7. PubMed ID: 7196685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.
    McGovern B; Garan H; Malacoff RF; DiMarco JP; Grant G; Sellers TD; Ruskin JN
    Am J Cardiol; 1984 Jun; 53(11):1558-63. PubMed ID: 6731300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G; Ciaccheri M; Cecchi F; Troiani V; Nannini M; Marconi P; Olivotto J; Montereggi A; Dolara A
    G Ital Cardiol; 1999 May; 29(5):514-23. PubMed ID: 10367218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy.
    Fananapazir L; Leon MB; Bonow RO; Tracy CM; Cannon RO; Epstein SE
    Am J Cardiol; 1991 Jan; 67(2):169-74. PubMed ID: 1987718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation.
    Morady F; Scheinman MM; Hess DS
    Pacing Clin Electrophysiol; 1983 May; 6(3 Pt 1):609-15. PubMed ID: 6191299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arrhythmia and prognosis in hypertrophic cardiomyopathy.
    McKenna WJ
    Eur Heart J; 1983 Nov; 4 Suppl F():225-34. PubMed ID: 6686539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ambulatory ECG in cardiomyopathies].
    Mestroni L; Miani D; Neri R; Di Lenarda A; Camerini F
    G Ital Cardiol; 1987 Dec; 17(12):1139-44. PubMed ID: 3503812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does treatment influence the natural history of patients with hypertrophic cardiomyopathy?
    McKenna WJ
    Drugs; 1985 Mar; 29 Suppl 3():53-6. PubMed ID: 4039653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiarrhythmic efficacy of amiodarone in recurrent ventricular tachycardia evaluated by multiple electrophysiological and ambulatory ECG recordings.
    Rasmussen K; Winkle R; Ross D; Griffin J; Peters F; Mason J
    Acta Med Scand; 1982; 212(6):367-74. PubMed ID: 6760675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term-treatment of ventricular tachycardia in ambulatory patients with amiodarone.
    Vazquez Blanco M; Milei J; Piñeiro DJ; Buceta JE; Dreyer MP
    Acta Cardiol; 1983; 38(2):125-32. PubMed ID: 6603085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiodarone in the treatment of life-threatening ventricular tachycardia: role of Holter monitoring in predicting long-term clinical efficacy.
    Veltri EP; Reid PR; Platia EV; Griffith LS
    J Am Coll Cardiol; 1985 Oct; 6(4):806-13. PubMed ID: 3928726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of electrophysiologic studies in hypertrophic cardiomyopathy treated with amiodarone.
    Fananapazir L; Epstein SE
    Am J Cardiol; 1991 Jan; 67(2):175-82. PubMed ID: 1987719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sudden death in hypertrophic and dilated cardiomyopathy.
    Koga Y; Ogata M; Kihara K; Tsubaki K; Toshima H
    Jpn Circ J; 1989 Dec; 53(12):1546-56. PubMed ID: 2632825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amiodarone in refractory life-threatening ventricular arrhythmias.
    Nademanee K; Singh BN; Hendrickson J; Intarachot V; Lopez B; Feld G; Cannom DS; Weiss JL
    Ann Intern Med; 1983 May; 98(5 Pt 1):577-84. PubMed ID: 6846970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of recurrent supraventricular tachycardia with amiodarone hydrochloride.
    Swan JH; Chisholm AW
    Can Med Assoc J; 1976 Jan; 114(1):43-4. PubMed ID: 943223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.